---
title: "Nanjing Leads Biolabs Wins FDA Fast Track Status for Multiple Myeloma Drug LBL-034"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273910861.md"
description: "Nanjing Leads Biolabs Co., Ltd. has received Fast Track Designation from the FDA for its drug LBL-034, aimed at treating relapsed/refractory multiple myeloma. This designation follows previous Orphan Drug status and promising early clinical data. The company aims to enhance FDA interactions and expedite review timelines, highlighting both the drug's potential and associated development risks. Analysts rate the stock (HK:9887) as a Buy with a price target of HK$80.27, while the company focuses on innovative therapies for serious cancers."
datetime: "2026-01-28T00:38:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273910861.md)
  - [en](https://longbridge.com/en/news/273910861.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273910861.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273910861.md) | [繁體中文](https://longbridge.com/zh-HK/news/273910861.md)


# Nanjing Leads Biolabs Wins FDA Fast Track Status for Multiple Myeloma Drug LBL-034

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has shared an update.

Nanjing Leads Biolabs has announced that its bispecific T-cell engager candidate LBL-034, which targets both GPRC5D and CD3 to redirect and activate T cells against GPRC5D-positive cancer cells, has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory multiple myeloma. The designation, which follows earlier Orphan Drug status and promising preclinical and early clinical data including a high-profile presentation at the 2025 ASH conference, is expected to facilitate closer FDA interaction and potentially accelerate review timelines, strengthening the company’s position in the competitive multiple myeloma space while underscoring both the therapeutic potential of LBL-034 and the development risks that still remain for investors.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

**More about Nanjing Leads Biolabs Co., Ltd. Class H**

Nanjing Leads Biolabs Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative biologic therapies, particularly bispecific T-cell engagers, for serious cancers such as malignant plasma cell neoplasms and relapsed/refractory multiple myeloma, leveraging its proprietary LeadsBody CD3 T-cell engager platform to address unmet medical needs in oncology.

**Average Trading Volume:** 545,227

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$11.77B

For an in-depth examination of 9887 stock, go to TipRanks’ Overview page.

### 相关股票

- [LEADS BIOLABS-B (09887.HK)](https://longbridge.com/zh-CN/quote/09887.HK.md)

## 相关资讯与研究

- [BullFrog AI Signs Major AI Drug Discovery Partnership](https://longbridge.com/zh-CN/news/281092205.md)
- [14:37 ETLevrx and Waltz Health Partner to Expand Access to Transparent Pharmacy Pricing](https://longbridge.com/zh-CN/news/281411704.md)
- [TippingPoint Biosciences Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancer](https://longbridge.com/zh-CN/news/281175947.md)
- [Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP](https://longbridge.com/zh-CN/news/281557680.md)
- [08:27 ETinThought Announces the Promotion of Dr. Amanda Weyerbacher to Executive VP](https://longbridge.com/zh-CN/news/281186594.md)